Apr 29 |
Psychedelic drug developers could benefit from NIH funding for chronic pain
|
Apr 24 |
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
|
Apr 17 |
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
|
Apr 3 |
Atai Life Sciences upgraded at Maxim on Beckley investment
|
Apr 1 |
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
Mar 28 |
ATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04
|
Mar 28 |
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
|
Mar 27 |
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
|
Mar 16 |
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
|
Mar 12 |
atai Life Sciences advances VLS-01 for treatment-resistant depression
|